Clinical Trial Update: Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating alpha-1 antitrypsin (AAT) to enhance islet autograft survival in chronic pancreatitis has completed Phase 1/2 with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatitis

Drugs mentioned

• Alpha-1 Antitrypsin (alpha-1 antitrypsin)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Chronic Pancreatitis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-05-09